Topline data were announced from a phase 3 trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial ...

abdominal fat increases (from +1.23% to +4.21%), while muscle mass in the limbs decreases (from -0.81 kg to -2.63 kg). However, the BMI hardly changes at all. This paradox reveals a major flaw in ...

Body mass index (BMI) is key method for measuring a ... and lower appendicular lean mass (ALM) by –0.81 kg to –2.63 kg with respect to the young-age group, revealing higher abdominal fat ...

abdominal fat increases (from +1.23% to +4.21%), while muscle mass in the limbs decreases (from -0.81 kg to -2.63 kg). However, the BMI hardly changes at all. This paradox reveals a major flaw ...

In women, these variations are more subtle, but a trend emerges: with age, abdominal fat increases (from +1.23% to +4.21%), while muscle mass in the limbs decreases (from -0.81 kg to -2.63 kg).